NDA 209899 · Bristol
Zeposia
Ozanimod Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 25, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
40
17 Phase 3, 7 recruiting
FAERS reports
8,477
2,297 serious, 91 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 16, 2026.
ZEPOSIA is indicated for the treatment of: relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. moderately to severely active ulcerative colitis (UC) in adults. ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ) Moderately to severely active ulcerative colitis (UC) in adults. ( 1 )
Mechanism: Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod has minimal or no activity on S1P 2 , S1P 3 , and S1P 4 . The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis and ulcerative colitis is unknown but may involve the reduction of lymphocyte migration into the central nervous system and intestine.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 30, 2024 Supplement 11 · Efficacy LabelLetter
- May 27, 2021 Supplement 1 · Efficacy · priority review LabelLetterReview
- Mar 25, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
- ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.23MG BASE · CAPSULE, ORAL · Prescription
- ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.46MG BASE · CAPSULE, ORAL · Prescription
- ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.92MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ozanimod" as an intervention, any sponsor and status, largest first.
- A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02576717 · 2,494 participants · Start Oct 16, 2015 · Primary completion Jan 5, 2023
Drug: RPC1063 · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Fresno, California · 175 sites in all
- Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)Pivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02294058 · 1,346 participants · Start Dec 3, 2014 · Primary completion Dec 22, 2016
Drug: Ozanimod; Interferon beta-1a and 2 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Berkeley, California · 224 sites in all
- Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02047734 · 1,320 participants · Start Dec 3, 2013 · Primary completion Mar 27, 2017
Drug: Ozanimod; Ozanimod placebo and 2 more · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Berkeley, California · 299 sites in all
- Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative ColitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02435992 · 1,012 participants · Start Jun 17, 2015 · Primary completion Mar 27, 2020
Drug: RPC1063; Placebo · For: Ulcerative Colitis
Sites: Sun City, Arizona; Tucson, Arizona; North Little Rock, Arkansas · 372 sites in all
- An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02531126 · 877 participants · Start Dec 2, 2015 · Primary completion Dec 19, 2024
Drug: RPC1063 · For: Ulcerative Colitis
Sites: Tucson, Arizona; Anaheim, California; Mission Hills, California · 41 sites in all
- An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseasePivotal-lookingTerminated
CelgeneBristol Myers Squibb (BMY)
NCT03467958 · 854 participants · Start Aug 24, 2018 · Primary completion Oct 31, 2024
Drug: Ozanimod · For: Crohn Disease
Sites: Peoria, Arizona; Scottsdale, Arizona; North Little Rock, Arkansas · 766 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseasePivotal-lookingTerminated
CelgeneBristol Myers Squibb (BMY)
NCT03440372 · 625 participants · Start Feb 27, 2018 · Primary completion Oct 1, 2024
Drug: Ozanimod · For: Crohn Disease
Sites: Peoria, Arizona; North Little Rock, Arkansas; Camarillo, California · 408 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue789
- multiple sclerosis relapse595
- drug ineffective553
- headache526
- product dose omission issue381
- dizziness356
- nausea288
- diarrhoea267
- colitis ulcerative263
- pain259
- back pain218
- fall197
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 243 |
| 2021 | 1,903 |
| 2022 | 1,705 |
| 2023 | 1,533 |
| 2024 | 1,481 |
| 2025 | 995 |
| 2026 | 617 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zeposia (Ozanimod Hydrochloride)
2024 spending
$91.0M
Beneficiaries
1,271
8,645 claims
Per beneficiary
$71,559
$292.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,103,131 |
| 2021 | $19,598,158 |
| 2022 | $37,767,664 |
| 2023 | $62,945,499 |
| 2024 | $90,951,573 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, et al. · Lancet Gastroenterol Hepatol 2022 · Systematic Review, Network Meta-Analysis
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.